GPCR NewsJul 1, 20221 minGPCR Industry NewsConfo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for ...July 2022 Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for rare diseases "29/06/2022...
GPCR NewsJun 1, 20221 minGPCR Industry NewsAccelerating GPCR Drug Discovery With Conformation-Stabilizing VHHsJune 2022 "G protein-coupled receptors (GPCRs) represent a major therapeutic target class as they play a key role in many (patho-)...
GPCR NewsMar 1, 20221 minGPCR Industry NewsConfo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment ...March 2022 Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment Of Neuropathic Pain "—...
GPCR NewsDec 1, 20211 minGPCR Industry NewsVIB spin-off Confo Therapeutics Enters Collaborative Agreement with RegeneronDecember 2021 "30/11/2021 Confo will work together with Regeneron to apply its GPCR drug discovery platform to enable functional antibody...